With its Alzheimer's trial flop still smarting, Biogen's infusing new blood into its board. But now, one nominee for the expanded slate is bowing out.
Catalent CEO John Chiminski withdrew from the race after his company bought a gene therapy player, Paragon Bioservices, creating a potential conflict of interest. And at least for now, Biogen isn’t planning to nominate a replacement.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,